Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: The APRIME study

Clinical and Experimental Nephrology

Volumn 15, Issue 6, 2011, Pages 848-853

  Morikawa, Akizuki ^a   Ishizeki, Kanaki ^b   Iwashima, Yasunori ^c   Yokoyama, Hiroki ^d   Muto, Eiji ^e   Oshima, Eiji ^f   Sekiguchi, Masatomo ^g   Miura, Takanori ^h   Itoh, Hiroshi ⁱ   Haneda, Masakazu ^b  

^a ASAHIKAWA RED CROSS HOSPITAL   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c Yoshida Hospital   (Japan)

^d Jiyugaoka Medical Clinic   (Japan)

^e ASAHIKAWA CITY HOSPITAL   (Japan)

^f Oshima Clinic   (Japan)

^g Sapporo Kosei General Hospital   (Japan)

^h Asahikawa Kosei General Hospital   (Japan)

ⁱ Ohotsukukai Hospital   (Japan)

Author keywords

Diabetic nephropathy; Microalbuminuria; Pioglitazone; Renin angiotensin system inhibitor

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIURETIC AGENT; ENALAPRIL; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; INSULIN; INSULIN DERIVATIVE; LISINOPRIL; LOSARTAN; METFORMIN; OLMESARTAN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RENIN INHIBITOR; SULFONYLUREA; TELMISARTAN; VALSARTAN;

ADULT; AGED; ALBUMINURIA; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; JAPAN; MALE; METFORMIN; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855277362     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0512-3     Document Type: Article

References (29)

1. CE Mogensen 1984 Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes N Engl J Med 310 356 360 6690964 10.1056/NEJM198402093100605 1:STN:280:DyaL2c%2FptlGjtA%3D%3D (Pubitemid 14179541)
2. E Erdmann 2006 Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes Int J Cardiol 107 147 153 15975669 10.1016/j.ijcard.2005.03.053 1:STN:280:DC%2BD28%2Fis1eqsA%3D%3D
3. T Nakamura C Ushiyama N Shimada K Hayashi H Ebihara H Koide 2000 Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients J Diabetes Complicat 14 250 254 11113686 10.1016/S1056-8727(00)00124-0 1:STN:280: DC%2BD3M%2FovVamtA%3D%3D
4. G Bakris G Viberti WM Weston M Heise LE Porter MI Feed 2003 Rosiglitazone reduces urinary albumin excretion in type 2 diabetes J Hum Hypertens 17 7 12 12571611 10.1038/sj.jhh.1001444 1:CAS:528:DC%2BD3sXptF2gsA%3D%3D (Pubitemid 36163426)
5. LG Bakris LM Ruilope SO McMorn WM Weston MA Heise MI Feed, et al. 2006 Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria J Hypertens 24 2047 2055 16957566 10.1097/01.hjh.0000244955.39491.88 1:CAS:528:DC%2BD28XptFWhsL4%3D (Pubitemid 44371272)
6. F Pistrosch K Herbrig B Kindel J Passauer S Fischer P Gross 2005 Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients Diabetes 54 2206 2211 15983223 10.2337/diabetes.54.7.2206 1:CAS:528: DC%2BD2MXmtVelt78%3D (Pubitemid 40911285)
7. M Hanefeld P Brunetti GH Schernthaner DR Matthews BH Charbonnel 2004 One-year glycemic control with a sulfonylurea plus pioglytazone versus a sulfonylurea plus metformin in patients with type 2 diabetes Diabetes Care 27 141 147 14693980 10.2337/diacare.27.1.141 1:CAS:528:DC%2BD2cXmvV2jtA%3D%3D (Pubitemid 38196723)
8. Y Miyazaki E Cersosimo C Triplitt RA DeFronzo 2007 Rosiglitazone decreases albuminuria in type 2 diabetic patients Kidney Int 72 1367 1373 17805239 10.1038/sj.ki.5002516 1:CAS:528:DC%2BD2sXhtlWjtrrL (Pubitemid 350126770)
9. G Schernthaner DR Matthews B Charbonnel M Hanefeld P Brunetti 2004 Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus J Clin Endocrinol Metab 89 6068 6076 15579760 10.1210/jc.2003-030861 1:CAS:528:DC%2BD2cXhtFSit77J (Pubitemid 39628416)
10. T Nakamura T Sugaya Y Kawagoe Y Ueda H Koide 2006 Effect of pioglitazone on urinary liver-type fatty acid binding protein concentrations in diabetes patients with microalbuminuria Diabetes Metab Res Rev 22 385 389 16506273 10.1002/dmrr.633 1:CAS:528:DC%2BD28XhtFChs77F (Pubitemid 44446434)
11. PA Sarafidis GL Bakris 2006 Protection of the kidney by thiazolidiones: an assessment from bench to bedside Kidney Int 79 1223 1233 10.1038/sj.ki. 5001620 (Pubitemid 44435173)
12. PA Sarafidis PC Stafylas PI Georgianos AN Saratzis AN Lasaridis 2010 Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis Am J Kidney Dis 55 835 847 20110146 10.1053/j.ajkd.2009.11.013 1:CAS:528:DC%2BC3cXntFeksb0%3D
13. G Viberti NM Wheeldon 2002 Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect Circulation 106 672 678 12163426 10.1161/01.CIR.0000024416.33113.0A 1:CAS:528:DC%2BD38XmvFSmsL8%3D (Pubitemid 34851925)
14. H Makino M Haneda T Babazono T Moriya S Ito Y Iwamoto INNOVATION Study Group, et al. 2007 Prevention of transition from incipient to overt nephropathy with termisartan in patients with type 2 diabetes Diabetes Care 30 1577 1578 17389334 10.2337/dc06-1998 1:CAS:528:DC%2BD2sXntlWkt7g%3D (Pubitemid 46871174)
15. The committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest. 2010;1:212-28.
16. S Matsuo E Imai M Horio Y Yasuda K Tomita K Nitta, et al. 2009 Revised equations for estimated GFR from serum creatinine in Japan Am J Kidney Dis 53 982 992 19339088 10.1053/j.ajkd.2008.12.034 1:CAS:528:DC%2BD1MXnslKku7c%3D
17. UK Prospective Diabetes Study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
18. Y Ohkubo H Kishikawa E Araki T Miyata S Isami S Motoyoshi, et al. 1995 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study Diabetes Res Clin Pract 28 103 117 7587918 10.1016/0168-8227(95)01064-K 1:CAS:528:DyaK2MXpsVWgtrs%3D
19. UK Prospective Diabetes Study (UKPDS) group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703-13.
20. HY Zhang SR Reddy TA Kotchen 1994 Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity Hypertension 24 106 110 8020998 (Pubitemid 24195412)
21. K Isshiki M Haneda D Koya S Maeda T Sugimoto R Kikkawa 2000 Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats Diabetes 49 1022 1032 10866056 10.2337/diabetes.49.6.1022 1:CAS:528:DC%2BD3cXjvFylu7s%3D (Pubitemid 30349426)
22. N Perico G Remuzzi 2007 Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes Kidney Int 72 1419 1421 18046419 10.1038/sj.ki.5002654 1:CAS:528:DC%2BD2sXhtlKltLrP (Pubitemid 350197959)
23. Z Xiong H Huang J Li Y Guan H Wang 2004 Anti-inflammatory effect of PPAR gamma in cultured human mesangial cells Ren Fail 26 497 505 15526907 10.1081/JDI-200031747 1:CAS:528:DC%2BD2cXpvFamsrs%3D (Pubitemid 39363280)
24. AD Dobrian SD Schriver AA Khraibi RL Prewitt 2004 Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity Hypertension 43 48 56 14638618 10.1161/01.HYP.0000103629.01745.59 1:CAS:528: DC%2BD3sXpvVeqtrw%3D (Pubitemid 38031910)
25. M Fukuda T Nakamura K Kataoka H Nako Y Tokutomi YF Dong, et al. 2010 Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice J Hypertens 28 340 352 19864959 10.1097/HJH.0b013e32833366cd 1:CAS:528:DC%2BC3cXos1Whug%3D%3D
26. HM Jin Y Pan 2007 Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy Kidney Blood Press Res 30 203 211 17575467 10.1159/000104089 1:CAS:528:DC%2BD2sXnsl2gurc%3D (Pubitemid 47076217)
27. A Sugawara K Takeuchi A Uruno Y Ikeda S Arima M Kudo, et al. 2001 Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells Endocrinology 142 3125 3134 11416035 10.1210/en.142.7.3125 1:CAS:528:DC%2BD3MXkslelt7s%3D (Pubitemid 32575551)
28. A Harte P McTernan R Chetty S Coppack J Katz S Smith, et al. 2005 Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone Circulation 111 1954 1961 15837949 10.1161/01.CIR.0000161954.17870.5D 1:CAS:528:DC%2BD2MXjtFalsb4%3D (Pubitemid 40570215)
29. A Storka E Vojtassakova M Mueller S Kapiotis DG Haider A Jungbauer, et al. 2008 Angiotensin inhibition stimulates PPARgamma and the release of visfatin Eur J Clin Invest 38 820 826 19021699 10.1111/j.1365-2362.2008.02025.x 1:CAS:528:DC%2BD1cXhsVOhtb%2FL